Piclidenoson In The Treatment Of Plaque Psoriasis

Piclidenoson In The Treatment Of Plaque Psoriasis Overview The study focused on evaluating the effectiveness and safety of piclidenoson (CF101), an orally bioavailable agonist for the A3 adenosine receptor (A3AR), in treating moderate-to-severe plaque psoriasis. The A3AR is known to be overexpressed in the skin and peripheral blood mononuclear cells of individuals

Secukinumab Therapy In Psoriasis

Secukinumab Therapy In Psoriasis Overview Psoriasis is a chronic skin condition characterized by immune-mediated inflammation, significantly affecting patients' quality of life. Secukinumab, an interleukin 17A inhibitor, has been employed as a systemic treatment for psoriasis. However, its long-term retention rates in a real-world setting in Japan have not been comprehensively studied. In

Psoriasis Risk In Children With High BMI

Psoriasis Risk In Children With High BMI Overview This study aimed to investigate the potential association between childhood body mass index (BMI) and the risk of psoriasis. Using publicly available summary statistics from genome-wide association studies (GWAS) that focused on childhood BMI in individuals of European descent (n=39,620), the researchers conducted a

Piclidenoson In The Treatment Of Plaque Psoriasis